KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities

Volume: 39, Issue: 1
Published: Oct 28, 2020
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, whose main molecular trait is the MAPK pathway activation due to KRAS mutation, which is present in 90% of cases. The genetic landscape of KRAS wild type PDAC can be divided into three categories. The first is represented by tumors with an activated MAPK pathway due to BRAF mutation that occur in up to 4% of cases. The second includes tumors with microsatellite instability (MSI) due to...
Paper Details
Title
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
Published Date
Oct 28, 2020
Volume
39
Issue
1
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.